Literature DB >> 19732831

Dihydrotestosterone is a determinant of calcaneal bone mineral density in men.

Ramachandran Ilangovan1, Sivanandane Sittadjody, Muthusamy Balaganesh, Ramadoss Sivakumar, Bhaskaran Ravi Sankar, Karundevi Balasubramanian, Subramanian Srinivasan, Chinappa Subramanian, David M Thompson, Lurdes Queimado, Narasimhan Srinivasan.   

Abstract

Male osteoporosis is an increasingly important health problem worldwide. Though androgen deficiency leads to bone loss in men, information on the relative contribution of aromatizable and non-aromatizable androgens in maintaining bone mineral density (BMD) and the mechanisms involved are unclear. This cross-sectional study was designed to explore the same. Hundred osteoporotic men with age matched normal were studied for serum levels of sex steroids, PTH, IGF system components, cytokines and bone turnover markers. Our findings show that serum DHT, IGF-I, IGF-II and IGFBP-3 levels were significantly decreased while IL-1beta and bone turnover markers were significantly increased in osteoporotic men compared to normal. Pearson correlation analysis revealed that serum DHT, IGF-I, IGF-II and IGFBP-3 levels were positively and strongly correlated with BMD, while serum IL-1beta levels were negatively correlated with BMD. Serum PTH, testosterone, estradiol, IGFBP-4, TNF-alpha, IL-4 and IFN-gamma levels were similar between the two groups. We observed that DHT levels significantly declined with age. However, the significant difference in DHT between the osteoporotic and normal groups is the same regardless of age. A multiple regression model adjusted for age demonstrated that DHT/BMD association is fairly stronger among those with osteoporosis than the normal. Our findings for the first time point out that DHT is an important determinant of BMD in men. Most importantly, the strong positive correlation of serum DHT with BMD offers new perspectives in understanding the role of non-aromatizable androgen in regulating bone metabolism in men, and might serve as a potential clinical marker in the diagnosis of male osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732831     DOI: 10.1016/j.jsbmb.2009.08.004

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  4 in total

Review 1.  Insulin-like growth factors: actions on the skeleton.

Authors:  Shoshana Yakar; Haim Werner; Clifford J Rosen
Journal:  J Mol Endocrinol       Date:  2018-04-06       Impact factor: 5.098

2.  Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study.

Authors:  David Robinson; Hans Garmo; Pär Stattin; Karl Michaëlsson
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

3.  A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.

Authors:  Tony Antoniou; Erin M Macdonald; Zhan Yao; Tara Gomes; Mina Tadrous; Joanne M-W Ho; Muhammad M Mamdani; David N Juurlink
Journal:  BMC Musculoskelet Disord       Date:  2018-05-22       Impact factor: 2.362

4.  Testosterone, dihydrotestosterone, bone density, and hip fracture risk among older men: The Cardiovascular Health Study.

Authors:  Emily A Rosenberg; Petra Bůžková; Howard A Fink; John A Robbins; Molly M Shores; Alvin M Matsumoto; Kenneth J Mukamal
Journal:  Metabolism       Date:  2020-10-12       Impact factor: 13.934

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.